LEARNING OBJECTIVES
Upon completion of this activity, participants will be able to:
• Evaluate the effects of neurotransmitters and genes on psychotropic drug treatment;
• Study the Interface between neurology and psychiatry;
• Describe the pharmacologic treatment of schizophrenia with particular reference to the prodromal period and first episode;
• Outline the emerging theories and treatments of bipolar disorder, depression, treatment resistant depression, bipolar depression, stress and anxiety disorder;
• Discuss the role of psychotropic medications in women’s mental health with an emphasis on PMS, pregnancy, nursing, and the postpartum period;
• Review the appropriate use of medications in the treatment of sleep disorders;
• Access psychopharmacologic treatment of eating disorders;
• Summarize the interface between medicine and psychiatric disorders with an emphasis on cardiovascular disease and cancer;
• Review the appropriate use of stimulants in the treatment of attention and ADHD disorders as well as their use as an adjunct to antidepressant treatment;
• Identify psychopharmacologic treatment for the borderline personality disorder;
• Explain the role of psychopharmacology in the treatment of substance use disorders with particular emphasis on alcohol, opiates, and cannabis;
• Recognize when to utilize ECT and TMS for the treatment of depression;
• Discuss standard psychopharmacologic treatments that have now been proven to be ineffective;
• Give examples of the latest advances and problems associated with treatment approaches in the child, adolescent and geriatric populations.